Blood-Based Exosome Test Detects Early Gastric Cancer With 97% Accuracy

Gastric cancer is the fifth most common cancer and third leading cause of cancer death worldwide, yet roughly 60% of cases are diagnosed at advanced, incurable stages. Endoscopic screening, while effective in high-prevalence nations like Japan and Korea, is invasive, expensive, and impractical for widespread global adoption. Existing blood protein markers like CEA and CA19-9 have poor sensitivity and specificity for early disease, creating an urgent unmet need for a reliable, minimally invasive screening tool.

The DESTINEX multicenter study addressed this gap through a rigorous four-phase biomarker development pipeline. Phase one used small RNA sequencing on 189 specimens—including 47 matched tumor/normal tissue pairs and serum fractions—to identify differentially expressed miRNAs. Bioinformatic filtering narrowed the field to candidate panels of cell-free and exosomal miRNAs. Phases two and three applied machine learning to train and independently validate these panels in 263 and 217 serum specimens respectively, collected from four major referral centers in Japan and South Korea. Phase four tested the signature against other gastrointestinal cancers and paired pre/post-surgical samples.

The final Destinex signature comprises 10 exosomal miRNAs, distilled from an initial 17-miRNA combined panel (8 cell-free + 9 exosomal). In training, the 17-miRNA panel achieved an AUC of 96.3% (95% CI, 94.3%–98.4%); in independent validation, 95.3% (95% CI, 92.8%–97.9%). Critically, for early-stage pT1 gastric cancer—the window where curative surgery is most effective—Destinex alone achieved an AUC of 96.8% (95% CI, 93.5%–100%), with high sensitivity and specificity. The researchers also observed that five miRNAs overlapped between the cell-free and exosomal panels and performed comparably on their own, suggesting redundancy that may aid future assay simplification.

A key validation step was the longitudinal analysis of paired pre- and post-operative serum samples from 20 patients. MiRNA expression levels dropped significantly three months after tumor resection, confirming that the signal originates from tumor-derived exosomes rather than systemic inflammatory noise. Decision curve analysis and calibration curves further supported the clinical utility of the assay across a range of threshold probabilities.

The study's implications extend beyond screening. Exosomal miRNAs are biologically compelling because tumor cells secrete roughly ten times more exosomes than normal cells, and exosomal packaging protects miRNAs from degradation, making them more stable and cancer-specific than free circulating miRNAs. The authors draw on their group's prior success applying a similar combined cell-free/exosomal miRNA strategy to early pancreatic cancer detection, suggesting a platform approach may be generalizable across GI malignancies. If prospectively validated in lower-prevalence Western populations and across diverse ancestries, Destinex could provide a cost-effective, scalable first-line screening option for populations where endoscopy is inaccessible.